Squaric acid dibutyl ester is under clinical development by Squarex Pharmaceutical and currently in Phase I for Herpes Labialis (Oral Herpes). According to GlobalData, Phase I drugs for Herpes Labialis (Oral Herpes) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Squaric acid dibutyl ester LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Squaric acid dibutyl ester overview
Squaric acid dibutyl ester is under development for the treatment of herpes labialis (Cold Sore). The therapeutic candidate is a 2 percent solution of squaric acid dibutyl ester which is applied topically in patch form.
It was also under development for the treatment of genital herpes and oral herpes.
Squarex Pharmaceutical overview
Squarex Pharmaceutical is a biotechnology company that is engaged in the research and development of treatment for cold sores. The company is headquartered in Saint Paul, Minnesota, the US.
For a complete picture of Squaric acid dibutyl ester’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
